Tachycardia in Cancer Patients May Signal Increased Mortality Risk

Cancer patients who experienced tachycardia within one year of cancer diagnosis had higher mortality rates up to 10 years after diagnosis of tachycardia, according to research presented at the American College of Cardiology’s Advancing the Cardiovascular Care of the Oncology Patient conference. The course convenes in Washington on Jan. 25-27, 2019, bringing together top experts in both cardiology and oncology to review new and relevant science in this rapidly evolving field.

Sinus tachycardia is when the heart beats faster than normal while at rest and may cause palpitations and discomfort. In addition to cancer treatment, it can also occur as a result of other conditions such as blood clots that cause heart attack or stroke, heart failure, fainting or sudden death. In the study, researchers defined sinus tachycardia as a heart rate over 100 beats per minute (bpm) diagnosed via electrocardiogram.

“Tachycardia is a secondary process to an underlying disease and reflective of significant multi-system organ stress and disease in cancer patients,” said Mohamad Hemu, MD, a resident at Rush University Medical Center in Chicago and one of the study authors. “As a result, the most important initial step is to figure out what is causing the tachycardia. Reversible causes like dehydration and infections should be ruled out. Additionally, cardiopulmonary processes such as pulmonary embolism and other arrhythmias must be taken into consideration. Once these and all other causes of tachycardia are ruled out, then it is more likely that sinus tachycardia is a marker of poorer prognosis in these patients.”

Researchers analyzed 622 cancer patients, including lung cancer, leukemia, lymphoma or multiple myeloma, from Rush University Medical Center from 2008 to 2016. The patients were 60.5 percent women, 76.4 percent white and an average age of 70 years; 69.4 percent of the cohort was classified with stage 4 cancer and 43 percent had lung cancer. The study included 50 patients with tachycardia and 572 control patients without tachycardia. Patients included in the study had tachycardia at more than three different clinic visits within one year of diagnosis, excluding history of pulmonary embolism, thyroid dysfunction, ejection fraction less than 50 percent, atrial fibrillation and a heart rate over 180 bpm.

Researchers assessed mortality for patients adjusting for age and other characteristics that were significantly different between a heart rate of more than 100 bpm and less than 100 bpm, characteristics included race, albumin, hemoglobin, beta blockers, kidney disease, use of blood thinners, and type of cancer. They also examined mortality adjusting for age and other clinically relevant characteristics, such as race, coronary artery disease, stroke, diabetes, smoking and radiation. Tachycardia was a significant predictor of overall mortality in both models. Of the patients who experienced tachycardia, 62 percent died within 10 years of diagnosis compared to 22.9 percent of the control group.

“We are continuously learning about the unique heart disease risks that face cancer patients, and our study shows that tachycardia is a strong prognosticator regardless of cancer type. That’s why it is critically important to be co-managing both cancer and heart conditions to ensure patients receive the most effective treatment possible,” said senior author Tochi M. Okwuosa, DO, director of the cardio-oncology program at Rush University Medical Center. “However, we need to do more studies to determine whether management of tachycardia in cancer patients will have any effect on survival.”

U.S. Food and Drug Administration's Center for Devices and Radiological Health is taking a number of important steps to update its Medical Device Reporting (MDR) Program, one of the tools the FDA uses to monitor device performance, detect potential device-related safety concerns or signals and contribute to the benefit-risk assessment of these products.

President Kristy L. Weber, MD, “While the AAOS supports removing patients from the middle of out-of-network billing disputes, we strongly believe that imposing an insurer-controlled rate is not the solution. The Lower Health Care Costs Act represents an unprecedented transfer of market power by the government to insurers and directly threatens the independent practice of medicine."

The American College of Cardiology welcomes Ranna Parekh, MD, MPH, as its first Director of Diversity and Inclusion. By working with the ACC Task Force on Diversity and Inclusion and other societies and organizations, Parekh will lead and expand the College’s diversity and inclusion initiatives to create a more diverse and inclusive environment within the field of cardiovascular disease and strive for a fully inclusive organization and profession.

The preliminary outline for the Protecting People From Surprise Medical Bills Act strikes a necessary balance by providing strong patient protections, while simultaneously improving transparency, promoting access to appropriate medical care and avoiding the creation of disincentives for insurers and health care providers to negotiate network participation contracts in good faith.

“Unanticipated medical bills can have a profound effect on patient health care costs and the physician-patient relationship. Especially during a time when rapid market consolidation is driving up costs, decreasing patient choice, and inhibiting industry competition. The problem is further exacerbated as health insurance plans increasingly offer narrow, often inadequate networks of providers.

On behalf of our patients, ACC members thank the Senators for their efforts to reduce youth tobacco use and stand ready to partner with them—and other members of Congress—to enact strong legislation establishing a federal age of 21 for the sale of all tobacco products.”

Leaders from the 43 national medical organizations and the American Bar Association attended the historic meeting on February 10-11 in Chicago, which was hosted by the American College of Surgeons Committee on Trauma (ACS COT).

This award recognizes significant contributions to the field of diabetes epidemiology. Dr. Mayer-Davis will be recognized with this honor at the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco. She will deliver her Kelly West Award Lecture titled, “Improving Outcomes—Translating Epidemiology to Clinical Trials,” on Sunday, June 9.

The American Diabetes Association® (ADA) will present the 2019 Outstanding Scientific Achievement Award (OSAA) to Sadaf Farooqi, MB, ChB (Hons), PhD. Dr. Farooqi will be recognized with this honor, which is given annually for research in diabetes that demonstrates particular independence of thought and originality, during the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco. She will deliver her OSAA Lecture, titled “Obesity and the Biology of Weight Regulation,” during the National Scientific and Health Care Achievement Awards Presentation on Monday, June 10.

May is the first ever National Stop the Bleed Month, featuring training courses around the country to teach bleeding control techniques to the general public and empower them with the skills and knowledge to assist severely bleeding persons. During this month, an additional focus will be directed to May 23, which is the nation’s second annual National Stop the Bleed Day.

4/8/19: That approach would also likely result in thousands more women enduring extensive surgery, mastectomies and chemotherapy for advanced cancers - and do little to nothing to address overdiagnosis or the harms of screening named in the ACP guidelines.

We use cookies to improve the performance of our website, to analyze the traffic to our website, and to personalize your experience. If you continue to use this website without changing your settings, you agree that cookies may be placed on your device in accordance with our cookie policy. For detailed guidance on how to control or disable cookies, we recommend you visit https://www.aboutcookies.org. Some features of our website and application may not function properly if you change or disable Internet cookies. To find our more about our cookie policy on this website, see our Privacy Policy.

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

disable

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.